Switch	O
enhancers	O
interpret	O
TGF	O
-	O
beta	O
and	O
Hippo	O
signaling	O
to	O
control	O
cell	O
fate	O
in	O
human	O
embryonic	O
stem	O
cells	O
.	O


A	O
small	O
toolkit	O
of	O
morphogens	O
is	O
used	O
repeatedly	O
to	O
direct	O
development	O
,	O
raising	O
the	O
question	O
of	O
how	O
context	O
dictates	O
interpretation	O
of	O
the	O
same	O
cue	O
.	O


One	O
example	O
is	O
the	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
pathway	O
that	O
in	O
human	O
embryonic	O
stem	O
cells	O
fulfills	O
two	O
opposite	O
functions	O
:	O
pluripotency	O
maintenance	O
and	O
mesendoderm	O
(	O
ME	O
)	O
specification	O
.	O


Using	O
proteomics	O
coupled	O
to	O
analysis	O
of	O
genome	O
occupancy	O
,	O
we	O
uncover	O
a	O
regulatory	O
complex	O
composed	O
of	O
transcriptional	O
effectors	O
of	O
the	O
Hippo	O
pathway	O
(	O
TAZ	O
/	O
YAP	O
/	O
TEAD	O
)	O
,	O
the	O
TGF	O
-	O
beta	O
pathway	O
(	O
SMAD2	O
/	O
3	O
)	O
,	O
and	O
the	O
pluripotency	O
regulator	O
OCT4	O
(	O
TSO	O
)	O
.	O


TSO	O
collaborates	O
with	O
NuRD	O
repressor	O
complexes	O
to	O
buffer	O
pluripotency	O
gene	O
expression	O
while	O
suppressing	O
ME	O
genes	O
.	O


Importantly	O
,	O
the	O
SMAD	O
DNA	O
binding	O
partner	O
FOXH1	O
,	O
a	O
major	O
specifier	O
of	O
ME	O
,	O
is	O
found	O
near	O
TSO	O
elements	O
,	O
and	O
upon	O
fate	O
specification	O
we	O
show	O
that	O
TSO	O
is	O
disrupted	O
with	O
subsequent	O
SMAD	O
-	O
FOXH1	O
induction	O
of	O
ME	O
.	O


These	O
studies	O
define	O
switch	O
-	O
enhancer	O
elements	O
and	O
provide	O
a	O
framework	O
to	O
understand	O
how	O
cellular	O
context	O
dictates	O
interpretation	O
of	O
the	O
same	O
morphogen	O
signal	O
in	O
development	O
.	O
